Halia Therapeutics
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
Halia Therapeutics is a clinical-stage biotech developing first-in-class therapies for inflammasome-driven diseases via the NEK7–NLRP3 pathway. Its lead program, ofirnoflast (HT-6184), is in development for lower-risk myelodysplastic syndromes (LR-MDS), with positive Phase 2 data showing multilineage hematologic improvement, durable transfusion independence, and favorable tolerability in heavily pretreated patients. Halia's platform, born from discoveries in genetic resilience biology, identifies and therapeutically replicates naturally protective pathways linked to chronic inflammatory disease. Beyond hematology, Halia is advancing programs in neurodegeneration, systemic inflammation, and cardiometabolic disease, including HT-4253, a brain-penetrant LRRK2 inhibitor for Alzheimer's prevention. Halia combines human genetics, translational biology, and clinical validation to develop precision therapies that target chronic inflammation at its source rather than broadly suppress immunity.
Company HQ City:
Lehi
Company HQ State:
Utah
Company HQ Country:
United States
Year Founded:
2017
Lead Product in Development:
Ofirnoflast (HT-6184) — a first-in-class oral NEK7 allosteric modulator designed to inhibit NLRP3 inflammasome-driven inflammation. The program is currently being developed for lower-risk myelodysplastic syndromes (LR-MDS), where Phase 2 data demonstrated multilineage hematologic improvement, durable transfusion independence, and favorable tolerability in heavily pretreated patients.
Additional pipeline programs include HT-4253 for Alzheimer’s disease prevention and other inflammation-driven indications.
CEO
Dr. David Bearss PhD
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
June 2026 – Q3 2026
What is your next catalyst (value inflection) update?
Halia Therapeutics’ upcoming value inflection milestones include presentation of final Phase 2 clinical data for ofirnoflast (HT-6184) in lower-risk myelodysplastic syndromes (LR-MDS) during an oral presentation at the European Hematology Association (EHA) Congress 2026, highlighting multilineage hematologic improvement, durable transfusion independence, and favorable safety in heavily pretreated patients.
Additional near-term catalysts include completion of End-of-Phase 2 regulatory interactions with the FDA and initiation of a dose-optimization / safety run-in study designed to support and de-risk the subsequent registrational Phase 3 program in LR-MDS. The company believes recent FDA feedback provides increased clarity around the pivotal development pathway and broader strategic positioning within the evolving LR-MDS treatment landscape.
Halia also plans to initiate the HT-4253 Alzheimer’s disease early-intervention clinical study, advancing the company’s broader genetic resilience and neuroinflammation platform.
Further anticipated milestones include completion of the company’s Series D financing and continued strategic partnering discussions across hematology, neurodegeneration, and inflammasome-driven diseases.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}